title: Atrial natriuretic peptide distribution in fetal and failed adult human hearts.
abstract: The distributions of atrial natriuretic peptide (ANP) in human hearts during the developmental stage and in adult pathological states was examined with an antibody specific to human alpha-ANP. With immunoblotting and immunofluorescence methods, we found that a 17-kDa protein, which is a pro ANP, was expressed in human fetal ventricles, in which the numbers of myofibers containing ANP granules were more abundant in the subendocardial region than the subepicardial region. As determined by radioimmunoassay, the content of immunoreactive ANP (per milligram protein) in the developing heart was greatest in the left atrium and occurred decreasingly in the right atrium, right ventricle, and left ventricle, respectively. Because ANP content in the left ventricle declined during the progress of gestation in developing hearts and because it was very low, if ever detectable, in normal adult hearts, ventricular ANP expression appears to be developmentally regulated from the early gestational stage. However, it was reexpressed in the ventricles of patients who had suffered from severe congestive heart failure. In this situation, we found that the ventricular ANP expression was more marked in patients with dilated cardiomyopathy than in patients with severe valvular disease. Interestingly, in the ventricles of patients with dilated cardiomyopathy, ANP contents were higher in the left ventricular free wall than in the right ventricular free wall, although the left ventricular subendocardium contained more ANP than the subepicardium, showing a transmural gradient similar to that expressed in fetal ventricles. Thus, the expression of ANP in human ventricles is developmentally regulated from the early gestational stage, and even adult ventricular myofibers can synthesize ANP during severe congestive heart failure.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Third Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Tsuchimochi
authors.forename: F
authors.initials: F
authors.lastname: Kurimoto
authors.forename: K
authors.initials: K
authors.lastname: Ieki
authors.forename: H
authors.initials: H
authors.lastname: Koyama
authors.forename: F
authors.initials: F
authors.lastname: Takaku
authors.forename: M
authors.initials: M
authors.lastname: Kawana
authors.forename: S
authors.initials: S
authors.lastname: Kimata
authors.forename: Y
authors.initials: Y
authors.lastname: Yazaki
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D009320:Atrial Natriuretic Factor / Q000378:metabolism*; D002311:Cardiomyopathy, Dilated / Q000378:metabolism; D005260:Female; D005318:Fetal Heart / Q000378:metabolism*; D005455:Fluorescent Antibody Technique; D006321:Heart / Q000196:embryology*; D006333:Heart Failure / Q000378:metabolism; D006349:Heart Valve Diseases / Q000378:metabolism; D006801:Humans; D015151:Immunoblotting; D008297:Male; D008875:Middle Aged; D009206:Myocardium / Q000378:metabolism*; D009318:Natriuresis; D011498:Protein Precursors / Q000378:metabolism
chemical_list: D011498:Protein Precursors; D009320:Atrial Natriuretic Factor